tradingkey.logo

Medpace Holdings Inc

MEDP
542.040USD
+0.770+0.14%
Close 02/06, 16:00ETQuotes delayed by 15 min
15.23BMarket Cap
36.96P/E TTM

Medpace Holdings Inc

542.040
+0.770+0.14%

More Details of Medpace Holdings Inc Company

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

Medpace Holdings Inc Info

Ticker SymbolMEDP
Company nameMedpace Holdings Inc
IPO dateAug 11, 2016
CEOTroendle (August J)
Number of employees5900
Security typeOrdinary Share
Fiscal year-endAug 11
Address5375 Medpace Way
CityCINCINNATI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code45227-1543
Phone15135799911
Websitehttps://investor.medpace.com/
Ticker SymbolMEDP
IPO dateAug 11, 2016
CEOTroendle (August J)

Company Executives of Medpace Holdings Inc

Name
Name/Position
Position
Shareholding
Change
Dr. August J. Troendle, M.D.
Dr. August J. Troendle, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
646.18K
-29544.00%
Mr. Brian T. Carley
Mr. Brian T. Carley
Independent Director
Independent Director
26.34K
+62.00%
Mr. Jesse J. Geiger, CPA
Mr. Jesse J. Geiger, CPA
President
President
15.00K
-21503.00%
Mr. Stephen P. Ewald, J.D.
Mr. Stephen P. Ewald, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
13.34K
+3000.00%
Mr. Robert O. Kraft
Mr. Robert O. Kraft
Independent Director
Independent Director
946.00
+56.00%
Ms. Susan E. Burwig
Ms. Susan E. Burwig
Executive Vice President - Operations
Executive Vice President - Operations
--
--
Mr. Fred B. Davenport, Jr.
Mr. Fred B. Davenport, Jr.
Lead Independent Director
Lead Independent Director
--
--
Mr. Cornelius P. Mccarthy, III
Mr. Cornelius P. Mccarthy, III
Independent Director
Independent Director
--
--
Mr. Kevin M. Brady
Mr. Kevin M. Brady
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Femida H. Gwadry-Sridhar
Dr. Femida H. Gwadry-Sridhar
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. August J. Troendle, M.D.
Dr. August J. Troendle, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
646.18K
-29544.00%
Mr. Brian T. Carley
Mr. Brian T. Carley
Independent Director
Independent Director
26.34K
+62.00%
Mr. Jesse J. Geiger, CPA
Mr. Jesse J. Geiger, CPA
President
President
15.00K
-21503.00%
Mr. Stephen P. Ewald, J.D.
Mr. Stephen P. Ewald, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
13.34K
+3000.00%
Mr. Robert O. Kraft
Mr. Robert O. Kraft
Independent Director
Independent Director
946.00
+56.00%
Ms. Susan E. Burwig
Ms. Susan E. Burwig
Executive Vice President - Operations
Executive Vice President - Operations
--
--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
By BusinessUSD
Name
Revenue
Proportion
Metabolic
199.26M
30.19%
Oncology
192.63M
29.19%
Other
106.40M
16.12%
Central Nervous System
65.63M
9.94%
Cardiology
59.47M
9.01%
AVAI
36.52M
5.53%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Metabolic
199.26M
30.19%
Oncology
192.63M
29.19%
Other
106.40M
16.12%
Central Nervous System
65.63M
9.94%
Cardiology
59.47M
9.01%
AVAI
36.52M
5.53%

Shareholding Stats

Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Medpace Investors, L.L.C.
16.80%
The Vanguard Group, Inc.
8.01%
BlackRock Institutional Trust Company, N.A.
7.47%
AQR Capital Management, LLC
3.64%
Wasatch Global Investors Inc
3.29%
Other
60.79%
Shareholders
Shareholders
Proportion
Medpace Investors, L.L.C.
16.80%
The Vanguard Group, Inc.
8.01%
BlackRock Institutional Trust Company, N.A.
7.47%
AQR Capital Management, LLC
3.64%
Wasatch Global Investors Inc
3.29%
Other
60.79%
Shareholder Types
Shareholders
Proportion
Investment Advisor
47.10%
Investment Advisor/Hedge Fund
25.92%
Corporation
16.80%
Hedge Fund
6.46%
Research Firm
3.77%
Individual Investor
2.74%
Pension Fund
2.01%
Family Office
1.65%
Family Office
1.65%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1313
24.52M
87.06%
-4.75M
2025Q3
1221
26.75M
94.97%
-1.63M
2025Q2
1184
32.22M
114.46%
-1.64M
2025Q1
1189
32.19M
111.84%
-1.65M
2024Q4
1154
31.87M
104.30%
-1.77M
2024Q3
1089
31.75M
102.26%
-1.23M
2024Q2
1042
31.55M
102.01%
-1.83M
2024Q1
995
31.67M
102.27%
-1.17M
2023Q4
938
31.80M
103.67%
-407.87K
2023Q3
885
31.39M
102.53%
-1.87M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Medpace Investors, L.L.C.
4.73M
16.8%
--
--
Nov 28, 2025
The Vanguard Group, Inc.
2.28M
8.08%
-107.66K
-4.51%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.10M
7.47%
-112.24K
-5.06%
Sep 30, 2025
AQR Capital Management, LLC
1.03M
3.64%
+404.23K
+65.07%
Sep 30, 2025
Wasatch Global Investors Inc
925.96K
3.29%
-19.85K
-2.10%
Sep 30, 2025
State Street Investment Management (US)
673.14K
2.39%
-33.64K
-4.76%
Sep 30, 2025
Mawer Investment Management Ltd.
646.77K
2.3%
-170.66K
-20.88%
Sep 30, 2025
Troendle (August J)
646.18K
2.29%
-29.54K
-4.37%
Dec 03, 2025
Geode Capital Management, L.L.C.
642.67K
2.28%
+4.75K
+0.74%
Sep 30, 2025
D. E. Shaw & Co., L.P.
600.14K
2.13%
+256.58K
+74.68%
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Franklin Genomic Advancements ETF
5.91%
Invesco Dorsey Wright Healthcare Momentum ETF
5.53%
Argent Mid Cap ETF
5.35%
Aztlan Global Stock Selection DM SMID ETF
4.2%
Invesco S&P MidCap Quality ETF
4.17%
Invesco S&P MidCap 400 GARP ETF
3.39%
Janus Henderson Small/Mid Cap Growth Alpha ETF
3.14%
ERShares Entrepreneurs ETF
3.08%
Congress SMid Growth ETF
3%
Pacer US Large Cap Cash Cows Growth Leaders ETF
2.49%
View more
Franklin Genomic Advancements ETF
Proportion5.91%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion5.53%
Argent Mid Cap ETF
Proportion5.35%
Aztlan Global Stock Selection DM SMID ETF
Proportion4.2%
Invesco S&P MidCap Quality ETF
Proportion4.17%
Invesco S&P MidCap 400 GARP ETF
Proportion3.39%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion3.14%
ERShares Entrepreneurs ETF
Proportion3.08%
Congress SMid Growth ETF
Proportion3%
Pacer US Large Cap Cash Cows Growth Leaders ETF
Proportion2.49%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI